VIVUS Press Releases

Date	Title	Links
Toggle SummaryMarch 27, 2017	VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi VIVUS to Receive Commercial Rights to Africa, the Middle East, Turkey and the Commonwealth of Independent States, Including Russia	View HTML VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi 19.9 KB
Toggle SummaryJanuary 9, 2017	VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH) CAMPBELL, CA , and SAN CARLOS, CA -- (Marketwired) -- 01/09/17 -- VIVUS, Inc. ( NASDAQ : VVUS) and Selten Pharma, Inc. , announced VIVUS' acquisition from Selten of exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary	View HTML VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH) 18.8 KB

Press Releases